Results 281 to 290 of about 56,186 (320)
Some of the next articles are maybe not open access.
Toxicity of Aromatase Inhibitors
Seminars in Oncology, 2006Adjuvant hormonal therapy in hormone receptor-positive breast cancer is used for the prevention of disease recurrence and prolongation of survival. Aromatase inhibitors are increasingly being used for this purpose. Numerous studies now reveal their benefits over tamoxifen while demonstrating a markedly different toxicity profile.
Pandya, Naushira, Morris, G J
openaire +3 more sources
Aromatase inhibitors—Gene discovery
The Journal of Steroid Biochemistry and Molecular Biology, 2007Microarray analysis of tumour RNA is an extremely powerful tool which allows global gene expression to be measured. When used in combination with neoadjuvant treatment protocols in which therapy is given with the primary tumour within the breast, sequential biopsies may be analysed and results correlated with clinical and pathological response.
William R, Miller +10 more
openaire +2 more sources
The Journal of Steroid Biochemistry and Molecular Biology, 2007
In patients with hormone receptor positive DCIS tamoxifen reduces recurrence rates by almost 50%. Few data are available with aromatase inhibitors from randomised studies. In the ATAC study there were three DCIS lesions in the anastrozole arm and four in the tamoxifen arm in the women with ER positive invasive cancer. In the MA17 study which randomised
J Michael, Dixon +9 more
openaire +2 more sources
In patients with hormone receptor positive DCIS tamoxifen reduces recurrence rates by almost 50%. Few data are available with aromatase inhibitors from randomised studies. In the ATAC study there were three DCIS lesions in the anastrozole arm and four in the tamoxifen arm in the women with ER positive invasive cancer. In the MA17 study which randomised
J Michael, Dixon +9 more
openaire +2 more sources
Aromatase inhibitors in pediatrics
Nature Reviews Endocrinology, 2011Aromatase, an enzyme located in the endoplasmic reticulum of estrogen-producing cells, catalyzes the rate-limiting step in the conversion of androgens to estrogens in many tissues. The clinical features of patients with defects in CYP19A1, the gene encoding aromatase, have revealed a major role for this enzyme in epiphyseal plate closure, which has ...
Wit, J.M., Hero, M., Nunez, S.B.
openaire +3 more sources
Oncology Research and Treatment, 1998
Summary Tamoxifen still is the mainstay of endocrine therapy in women with advanced breast cancer. Response rates in hormone receptor-positive patients are reported in about 50%. Second-
T. Volm, V. Möbus, R. Kreienberg
openaire +1 more source
Summary Tamoxifen still is the mainstay of endocrine therapy in women with advanced breast cancer. Response rates in hormone receptor-positive patients are reported in about 50%. Second-
T. Volm, V. Möbus, R. Kreienberg
openaire +1 more source
Aromatase inhibitors and teratogenesis
Fertility and Sterility, 2004letter to the ...
openaire +2 more sources
The Journal of Steroid Biochemistry and Molecular Biology, 2007
The decrease in estrogen levels with the use of aromatase inhibitors results in an increase in the rate of bone remodelling. This result in an acceleration of bone loss, and probably to an increase in the risk of fractures. The risk of fracture is particularly high in the older woman and in the woman with a low bone mineral density. We have a number of
openaire +2 more sources
The decrease in estrogen levels with the use of aromatase inhibitors results in an increase in the rate of bone remodelling. This result in an acceleration of bone loss, and probably to an increase in the risk of fractures. The risk of fracture is particularly high in the older woman and in the woman with a low bone mineral density. We have a number of
openaire +2 more sources
Aromatase inhibitors ? mechanisms of steroidal inhibitors
Breast Cancer Research and Treatment, 1994Inhibition of aromatase has been an attractive approach for examining the roles of estrogen biosynthesis in various physiological or pathological processes. Effective aromatase inhibitors can serve as potential therapeutic agents for controlling estrogen-dependent diseases such as hormone-dependent breast cancer.
openaire +2 more sources